Olivier Bohuon elected to LEO Pharma’s Board of Directors
LEO Pharma expands its Board of Directors with Olivier Bohuon who will join as vice chairman. With extensive experience in global pharmaceuticals and medical technology, Bohuon will contribute significantly to realising LEO Pharma’s strategy of being a global leader in medical dermatology.
Ballerup, Denmark, August 28, 2018 – On August 27 an extraordinary general meeting elected Olivier Bohuon as a new member of LEO Pharma’s Board of Directors. He will serve as the Board of Directors’ new vice chairman.
“I am excited to welcome Olivier Bohuon to LEO Pharma’s Board of Directors,” said Jukka Pertola, Chairman of LEO Pharma’s Board of Directors. “Olivier brings extensive strategic and commercial expertise in the global pharma industry. This will benefit LEO Pharma greatly as we are expanding into new innovative treatments in our ambition of being a global leader in medical dermatology,” Pertola continued.
“LEO Pharma is a company with a very strong vision. Its focus area of medical dermatology is strongly growing, highly competitive and benefiting from scientific advances in biotechnology. I am delighted to be able to help LEO Pharma succeed with its ambitious strategy,” said Olivier Bohuon.
Olivier Bohuon brings extensive experience in the global pharmaceutical and med-tech industry. He is board member of Smiths Group plc, senior independent director at Shire plc, supervisory board member at Virbac SA, and member of the National Pharmacy Academy and the Academy of Technologies. From 2011 to May 2018 Bohuon served as CEO of medical equipment specialist Smith & Nephew plc. Before that, he held positions as CEO at Laboratories Pierre Fabre, EVP, pharmaceutical products at Abbott Laboratories and SVP, director of European Commercial Operations at GlaxoSmithKline.
- ENDS -
+45 3140 6180
Information om LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 130 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,200 people worldwide. For more information, visit www.leo-pharma.com
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases11.4.2019 11:40:51 CEST | Pressemeddelelse
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology9.4.2019 10:00:56 CEST | Pressemeddelelse
Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment19.3.2019 10:33:23 CET | Pressemeddelelse
Andernach, DE, and Ballerup, DK, March 19, 2019: LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients.
Olivier Bohuon elected new chairman of LEO Pharma’s Board of Directors28.2.2019 00:10:03 CET | Pressemeddelelse
BALLERUP, Denmark, 28 February 2019 – LEO Pharma today announced changes to its Board of Directors. Olivier Bohuon is announced new chairman of the Board of Directors succeeding Jukka Pertola, who has decided to leave the Board. Member of the Board Anders Ekblom will assume a new position as vice chairman. In addition, John Weeks decided to not seek re-election.
LEO Pharma Annual Results 2018: A year in line with expectations28.2.2019 00:08:59 CET | Pressemeddelelse
- 2018 revenue of DKK 10,410 million - Strong progress on 2025 Strategy - Strengthened innovative clinical pipeline - Expanded established portfolio
Forskere fra LEO Pharma hyldes med Innovationsfondens Innovatørpris 20191.2.2019 15:01:40 CET | Pressemeddelelse
Excellent og banebrydende forskning, som skaber værdi for Danmark, er i fokus, når Innovationsfonden i dag uddeler årets priser. Det er derfor med stor stolthed, at LEO Pharma i dag kan meddele, at to af virksomhedens forskere, Marianne Lind, Ph.d. Senior Scientist og Karsten Petersson, Ph.d. Director, er udvalgt til at modtage Innovatørprisen 2019. Det er tredje år i træk, at prisen uddeles, og tildelingen af årets Innovatørpris til Marianne Lind og Karsten Petersson, som begge arbejder inden Explorative Formulation & Technologies hos LEO Pharma, sker på baggrund af følgende vurderinger: Den værdiskabelse, kandidaterne har skabt for såvel virksomhed som patienter Kandidaternes evne til at omsætte excellent forskningsviden til konkrete løsninger De to forskere modtager prisen for udviklingen af Enstilar®, LEO Pharmas skumspray til behandling af psoriasis. Enstilar® blev godkendt af Lægemiddelstyrelsen og kom på markedet i Danmark i 2016. Produktet anvendes i dag af flere end en million
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum